Bullish View On Blink Charging; Pfizer Deal Boosts Ginkgo Bioworks
- September 27th, 2023
- 564 views
UBS has initiated coverage on Blink Charging Co. (Nasdaq: BLNK), a leading provider of electric vehicle charging services, with a Buy rating and a price target of $7.
With $BLNK closing at $2.93 on Tuesday, the price target suggests a significant potential upside of $4.07 or 138.85%, according to the investment services firm's evaluation.
In other news, Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) has unveiled a significant collaboration with Pfizer Inc. (NYSE: PFE), with a primary focus on pioneering RNA-based drug candidates. This partnership will see Pfizer harnessing Ginkgo's cutting-edge RNA technology to advance the discovery and development of innovative RNA molecules, particularly within key research domains.
As part of the deal, Ginkgo will receive an initial payment and stands to earn research fees, development milestones, and potential commercial payments, potentially amounting to a substantial $331 million across three distinct programs. Furthermore, Ginkgo may also realize downstream value through royalties based on sales.
$DNA was trading at $1.99 in pre-market, up $0.26 (+15.02%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Micron Technology, Jabil, and Birkenstock Earnings Preview: What to Expect
December 15th, 2024Upcoming Earnings: Synopsys, AeroVironment, and nCino in Focus
December 01st, 2024Countdown to Earnings: Salesforce, Marvell Technology, and Okta Take the Stage
December 01st, 2024Fluence Energy, Agilent Technologies, and Woodward Earnings On Deck: A Preview
November 24th, 2024Earnings Preview: Walt Disney, Applied Materials, and Celcuity Take Center Stage
November 11th, 2024
Member Login